Nanocurcumin supplementation ameliorates Behcet’s disease by modulating regulatory T cells: A randomized, double‐blind, placebo‐controlled trial
Nanocurcumin supplementation ameliorates Behcet’s disease by modulating regulatory T cells: A randomized, double‐blind, placebo‐controlled trial
نویسندگان: ثمانه عباسیان , محمدصادق سلطانی زنگبار , علیرضا خبازی اسکویی , روژین فرزانه , آیدا مالک مهدوی , رزا متولی خیاوی , مهرزاد حاج علیلوی بناب , مهدی یوسفی
کلمات کلیدی: Behçet's disease, Nanocurcumin, Regulatory T cells, Cytokines, MicroRNA.
نشریه: 55231 , 2021 , 101 , 2021
| نویسنده ثبت کننده مقاله |
آیدا مالک مهدوی |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
بیماری های بافت همبند |
| کد مقاله |
77207 |
| عنوان فارسی مقاله |
Nanocurcumin supplementation ameliorates Behcet’s disease by modulating regulatory T cells: A randomized, double‐blind, placebo‐controlled trial |
| عنوان لاتین مقاله |
Nanocurcumin supplementation ameliorates Behcet’s disease by modulating regulatory T cells: A randomized, double‐blind, placebo‐controlled trial |
| ناشر |
8 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
بلی |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| Current research was designed to assess the effects of nanocurcumin supplementation on regulatory T (Treg) cells frequency and function in Behçet's disease (BD). In this randomized double-masked, placebo-controlled trial, 36 BD subjects were randomly put into two groups to take one 80 mg nanocurcumin capsule or placebo daily for 8 weeks. Before and after trial, disease activity, Treg cells frequency and expression of related immunologic parameters including forkhead box protein P3 (Foxp3) transcription factor messenger RNA (mRNA) and microRNAs (miRNAs) such as miRNA-25 and miRNA-106b as well as cytokines including transforming growth factor (TGF)-β and interleukin (IL)-10 were studied. Thirty-two patients (17 in the nanocurcumin and 15 in the placebo groups) completed the trial. Treg cells frequency increased significantly in the nanocurcumin group compared with baseline (P < 0.001) and placebo group (P < 0.001). Moreover, FoxP3, TGF-β, IL‐10, miRNA-25, and miRNA-106b mRNA expression levels increased considerably in the nanocurcumin group compared to baseline (P < 0.001) and placebo group (P < 0.001, P < 0.001, P = 0.025, P = 0.011, and P < 0.001, respectively). Significant increases in serum TGF-β and IL-10 were seen in nanocurcumin group compared with baseline (P < 0.001) and placebo group (P = 0.001 and P < 0.001, respectively). Significant decrease in disease activity was found in nanocurcumin group compared with placebo group (P = 0.044). Our study provided a promising view for desirable effects of nanocurcumin supplementation in improving immunological parameters and disease activity in BD. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| 1.pdf | 1400/08/29 | 2310526 | دانلود |